 |
|
|
| |
Efficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
|
| |
| |
Reported by Jules Levin
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention,
July 19-22, Vancouver, Canada BC
Jose M. Gatell1, Francois Raffi2, Andreas Plettenberg3, Don Smith4, Joaquin Portilla5, Christian Hoffmann6, Keikawus Arasteh7, Melanie Thompson8, Debbie P. Hagins9, Javier O. Morales-Ramirez10, Xia Xu11, Hedy Teppler11 for the P007 Study Team
1Hospital Clinic/IDIBAPS, Univ of Barcelona, Barcelona, Spain; 2COREVIH Pays de Loire, France; 3 ifi-Institute for Infections, Hamburg, Germany; 4 Albion Centre, Sydney, Australia; 5 Univ Miguel Hernandez, Alicante, Spain; 6 ICH Study Center, Hamburg, Germany; 7 EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 8 AIDS Research Consortium of Atlanta, Atlanta, GA; 9 Chatham County Health Dept, Savannah, GA; 10 Clinical Research Puerto Rico, San Juan, PR; 11 Merck & Co., Inc., Kenilworth, NJ
Panel discussion: the implications from the START findings
https://www.youtube.com/watch?t=25&v=miM3umStJFE
|
| |
|
|
|
|
|
